| Target | Source | |||||
|---|---|---|---|---|---|---|
| FragID | (Sub)Section | Text | Section | Text in SummaryFragmentRef | In Table? | In List? |
| _1 | General Information About Adult Acute Lymphoblastic Leukemia (ALL) | adult acute lymphoblastic leukemia Prognosis--legacy General Information About Adult Acute Lymphoblastic Leukemia (ALL) ALL (also called acute lymphocytic leukemia) is an aggres | Changes to This Summary (02/13/2013) | General Information About Adult Acute Lymphoblastic Leukemia | ||
| _58 | Stage Information for Adult ALL | adult acute lymphoblastic leukemia Stage explanation--legacy Stage Information for Adult ALL There is no clear- | Treatment Option Overview | Disease Status | X | |
| _87 | Remission induction therapy | Remission induction therapy Sixty percent to 80% of adults with ALL usually achieve a complete remission (CR) status following appropria | Treatment Option Overview | Remission induction therapy | X | |
| Standard Treatment Options for Untreated Adult ALL | Remission induction therapy | X | ||||
| _101 | CNS prophylaxis therapy | CNS prophylaxis therapy The early institution of CNS prophylaxis is critical to achieve control of sanctuary disease. Consider adding text | Treatment Option Overview | CNS prophylaxis therapy | X | |
| Standard Treatment Options for Untreated Adult ALL | Central nervous system (CNS) prophylaxis therapy | X | ||||
| _111 | Postremission therapy | Postremission therapy Current approaches to postremission therapy for adult ALL include short-term, relatively intensive chemotherapy followed by | Treatment Option Overview | Postremission therapy | X | |
| Standard Treatment Options for Adult ALL in Remission | Postremission therapy | X | ||||
| _130 | CNS prophylaxis therapy | CNS prophylaxis therapy The early institution of CNS prophylaxis is critical to achieve control of sanctuary disease. Some authors have suggested | Treatment Option Overview | CNS prophylaxis therapy | X | |
| Standard Treatment Options for Adult ALL in Remission | Central nervous system (CNS) prophylaxis therapy | X | ||||
| _139 | Reinduction chemotherapy | Reinduction chemotherapy Patients with ALL who experience a relapse following chemotherapy and maintenance therapy are unlikely to be cured by fur | Treatment Option Overview | Reinduction chemotherapy | X | |
| Standard Treatment Options for Recurrent Adult ALL | Reinduction chemotherapy | X | ||||
| _141 | Palliative radiation therapy | Palliative radiation therapy Low-dose palliative radiation therapy may be considered in patients with symptomatic recurrence either within or outs | Treatment Option Overview | Palliative radiation therapy | X | |
| Standard Treatment Options for Recurrent Adult ALL | Palliative radiation therapy | X | ||||
| _143 | Dasatinib | Dasatinib Patients with Ph1-positive ALL will often be taking imatinib at the time of relapse and thus will have imatinib-resistant disease. Dasa | Treatment Option Overview | Dasatinib | X | |
| Standard Treatment Options for Recurrent Adult ALL | Dasatinib | X | ||||
| _222 | Cellular Classification of Adult ALL | Table Frequency of ALL Cell SubtypesCell SubtypeApproximate FrequencyEarly B-cell lineage80% T cells10%–15%B cells with surface immunoglobulins<5% | Cellular Classification of Adult ALL | None | ||
| _228 | Incidence and Mortality | Estimated new cases and deaths from ALL in the United States in 2013:Cancer Facts and Figures 2013 | Changes to This Summary (02/13/2013) | statistics | ||